← Return to (MAC/MAI) Mycobacterium Avium Complex Pulmonary Disease: Join us

Discussion

(MAC/MAI) Mycobacterium Avium Complex Pulmonary Disease: Join us

MAC & Bronchiectasis | Last Active: Oct 29 5:15pm | Replies (9350)
Comment receiving replies
@kathyhg

This discussion re: delays in getting lab results reminded me that we’re using drugs that were developed for other diseases as Mac/NTM is considered an orphan disease and hasn’t been profitable for pharmaceutical companies to invest in research and development.

It’s coming 2 years since I read on this forum that SPER Therapeutics was close to the trial phase in the development of a drug specifically for Mac/NTM. I haven’t heard anymore about whether they are getting closer to making this drug available.

Has anyone been following this?

Jump to this post

Replies to "This discussion re: delays in getting lab results reminded me that we’re using drugs that were..."
anniepie | @anniepie | Feb 22, 2021

Hi Kathy @kathyhg, I was wondering about the SPERO trial too. Here's a link to where they're at (as of 21 Feb 2021): https://www.centerwatch.com/clinical-trials/listings/255544/phase-2a-safety-tolerability-pharmacokinetics-and-efficacy-of-spr720-for-the-treatment-of-patients-with-mycobacterium-avium-complex-mac-pulmonary-disease/ ,

Clinical trials like this seem to take a very long time, compared to all the money thrown at Covid vaccines. They are still recruiting for their Phase 2a trial for the new NTM drug -- currently called SPR720. This phase is expected to finish in 2022, but then after that there will need to be a Phase 3 trial with a larger number of NTM patients. Just recruiting the number of NTM patients needed for trial phases seems to take a long time with NTMs, so it looks like the new drug is a long way off yet.
All the best, Annie

VIEW AND REPLY